Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure by Lutz, Thomas A
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Gut hormones such as amylin and GLP-1 in the control of eating and energy
expenditure
Lutz, Thomas A
Abstract: The control of meal size is the best studied aspect of the control of energy balance, and
manipulation of this system constitutes a promising target to treat obesity. A major part of this control
system is based on gastrointestinal hormones such as glucagon-like peptide-1 (GLP-1) or amylin, which
are released in response to a meal and which limit the size of an ongoing meal. Both amylin and GLP-
1 have also been shown to increase energy expenditure in experimental rodents, but mechanistically
we know much less how this effect may be mediated, which brain sites may be involved, and what the
physiological relevance of these findings may be. Most studies indicate that the effect of peripheral amylin
is centrally mediated via the area postrema, but other brain areas, such as the ventral tegmental area,
may also be involved. GLP-1’s effect on eating seems to be mainly mediated by vagal afferents projecting
to the caudal hindbrain. Chronic exposure to amylin, GLP-1 or their analogs decrease food intake and
body weight gain. Next to the induction of satiation, amylin may also constitute an adiposity signal and
in fact interact with the adiposity signal leptin. Amylin analogs are under clinical consideration for their
effect to reduce food intake and body weight in humans, and similar to rodents, amylin analogs seem to
be particularly active when combined with leptin analogs.
DOI: https://doi.org/10.1038/ijosup.2016.4
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-140847
Accepted Version
Originally published at:
Lutz, Thomas A (2016). Gut hormones such as amylin and GLP-1 in the control of eating and energy
expenditure. International Journal of Obesity Supplements, 6(Suppl 1):S15-S21.
DOI: https://doi.org/10.1038/ijosup.2016.4
Gut hormones like amylin and GLP-1 in the control of eating and energy 1 
expenditure 2 
 3 
Thomas A. Lutz1,2 4 
 5 
1Institute of Veterinary Physiology, Vetsuisse Faculty University of Zurich, Zurich, 6 
Switzerland;  7 
2Zurich Center of Integrative Human Physiology, University of Zurich, Zurich, 8 
Switzerland; 9 
 10 
 11 
Short title: Amylin and GLP-1 in the control of eating 12 
Correspondence: 13 
Thomas A. Lutz 14 
Institute of Veterinary Physiology 15 
Vetsuisse Faculty University of Zurich 16 
Winterthurerstrasse 260 17 
8057 Zurich 18 
Switzerland 19 
Telephone: +41-44-635 88 08 20 
Fax: +41-44-635 89 32 21 
Email: tomlutz@vetphys.uzh.ch 22 
23 
1 
Abstract 24 
The control of meal size is the best studied aspect of the control of energy balance, 25 
and manipulation of this system constitutes a promising target to treat obesity. A 26 
major part of this control system is based on gastrointestinal hormones like glucagon-27 
like peptide-1 (GLP-1) or amylin which are released in response to a meal and which 28 
limit the size of an ongoing meal. Both amylin and GLP-1 have also been shown to 29 
increase energy expenditure in experimental rodents but mechanistically, we know 30 
much less how this effect may be mediated, which brain sites may be involved, and 31 
what the physiological relevance of these findings may be. Most studies indicate that 32 
the effect of peripheral amylin is centrally mediated via the area postrema but other 33 
brain areas, like the ventral tegmental area may also be involved. GLP-1’s effect on 34 
eating seems to be mainly mediated by vagal afferents projecting to the caudal 35 
hindbrain. Chronic exposure to amylin, GLP-1 or their analogues decrease food 36 
intake and body weight gain.  37 
Next to the induction of satiation, amylin may also constitute an adiposity signal and 38 
in fact interact with the adiposity signal leptin. Amylin analogs are under clinical 39 
consideration for their effect to reduce food intake and body weight in humans, and 40 
similar to rodents, amylin analogues seem to be particularly active when combined 41 
with leptin analogues. 42 
 43 
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 Introduction 48 
The pancreatic B-cell hormone amylin and the gut-derived hormone glucagon-like 49 
peptide-1 (GLP-1) are released in response to food intake. Behaviorally, both 50 
hormones produce similar responses on eating and both hormones have the 51 
potential to reduce body weight when administered chronically. In fact, the GLP-1 52 
analogue liraglutide was recently approved as body weight lowering drug by the 53 
Federal Drug Administration in the USA.  54 
This review which is based on a presentation given at the Quebec Symposium on 55 
Obesity in November 2014, will briefly discuss some recent findings on amylin versus 56 
GLP-1 action. An extensive literature search on the topic of this review was carried 57 
out by using Pubmed (http://www.ncbi.nlm.nih.gov/pubmed/).  As will be discussed, 58 
and despite similar behavioral effects after amylin or GLP-1 administration, there 59 
seem to be important differences in the mechanisms that lead to the reduction in 60 
eating by amylin versus GLP-1. 61 
 62 
Production site and secretion of amylin and GLP-1 63 
It is generally believed that pancreatic beta-cells are the major source of circulating 64 
amylin and that meal-associated fluctuations of circulating amylin levels directly 65 
reflect changes in beta-cell secretion. These fluctuations and the postprandial 66 
increase in circulating amylin are the physiological basis for amylin’s effect on eating, 67 
in particular its effect on meal size 1, 2. We recently measured levels of amylin and 68 
insulin in hepatic portal vein blood samples because this vascular bed best reflects 69 
the secretion of beta-cell products into the circulation. The meal induced increase in 70 
circulating amylin occurs within a few minutes after meal onset and parallels the 71 
increase in plasma insulin3. 72 
GLP-1 is secreted from enteroendocrine cells that line the entire intestinal epithelium. 73 
The density of the GLP-1 producing L-cells increases in more distal parts of the small 74 
intestine and in the colon, however the total number of L-cells, at least in rats, is 75 
highest in the jejunum, including its proximal part4. L-cells express a large number of 76 
receptors or transporters that trigger L-cell secretion in response to a variety of 77 
stimuli; these include glucose, long or short chain fatty acids but also bile acids that 78 
act on the TGR5 receptor5. Which of these stimuli contributes most to the 79 
postprandial release of GLP-1 is still a matter of debate, in particular in individuals 80 
undergoing Roux-en-Y gastric bypass surgery (RYGB) who have largely elevated 81 
3 
secretions of postprandial GLP-16-11. GLP-1 is also produced in a subset of neurons 82 
in the nucleus of the solitary tract (NTS). The exact role of GLP-1 released from 83 
these neurons is still under investigation but they seem to be involved in the 84 
mediation of reduced eating in response to aversive stimuli or in sickness anorexia12. 85 
Further, recent data indicate that locally released GLP-1 also contributes to the 86 
physiological control of eating and body weight (e.g., 13-15) because the knockdown of 87 
GLP-1 in the NTS leads to increased eating, body weight and adiposity16. 88 
 89 
4 
Amylin and GLP-1 as satiation signals 90 
The best investigated function of amylin is the role as a signal of satiation 17. Amylin 91 
is believed to be a physiological controller of meal size 18, 19 because it meets the 92 
critical criteria for a physiological endocrine satiation signal. One important criterion is 93 
that the meal-contingent infusion of amylin into the portal vein dose-dependently 94 
reduced the size and duration of the ongoing meal and that the onset of this action 95 
occurred within minutes after administration2. The meal size effect of amylin 96 
appeared to be independent of the route of administration (e.g., 20-22), and similar 97 
observations have also been reported for GLP-123, 24.  98 
Administration of the amylin antagonist AC187 increased meal size25, underlining the 99 
physiological relevance of amylin’s effect. While the GLP-1 antagonist exendin-9 has 100 
been reported to increase eating under some conditions26, a specific effect of 101 
exendin-9 on meal size has not been observed consistently and may be weak (e.g., 102 
27-29). Finally, chronic administration of amylin, GLP-1 or their analogues have been 103 
shown to reduce body weight by reducing food intake30-32, and at least in the case of 104 
amylin, this was associated with decreased meal sizes over extended time periods30. 105 
 106 
 107 
Sites of amylin and GLP-1 action 108 
Amylin and GLP-1 produce similar activation patterns in the caudal hindbrain when 109 
assessed by c-Fos immunohistochemistry (e.g., 33-36) but the primary sites of action 110 
may differ between amylin and GLP-1. Most experiments support the idea that the 111 
satiating effect of peripheral amylin is mediated by direct humoral action on the area 112 
postrema (AP) in the hindbrain which lacks a functional blood brain barrier25, 30, 37-40. 113 
This evidence is e.g. based on experiments showing that amylin’s effect is abolished 114 
in rats with AP lesions but not by disrupting afferent nerve signaling from the 115 
periphery to the brain41-44. Further, AP administered amylin antagonists blocked the 116 
anorectic action of peripheral amylin25.  117 
Recent experiments indicate that the AP may not be the only primary receptive site 118 
for the action of peripheral amylin or its analogues, and that the ventral tegmental 119 
area (VTA) may also play a role in this respect45. The peripheral administration of the 120 
amylin receptor agonist salmon calcitonin (sCT) reduces eating by activating amylin 121 
receptors46, and this effect is blocked by the VTA administration of the amylin 122 
antagonist AC18747. How amylin (or sCT) may reach VTA neurons is unclear; the 123 
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VTA is protected by the blood brain barrier but amylin transport across the blood 124 
brain barrier has been described48, 49 so that direct VTA activation by peripheral 125 
amylin or sCT seems possible. It is however important to note that the rat amylin-1 126 
receptor is activated equally by amylin and the neurotransmitter calcitonin gene-127 
related peptide (CGRP)50, and, importantly, that the effects of both peptides at the 128 
amylin-1 receptor are blocked by AC187. Hence, it cannot be excluded that primary 129 
activation of AP neurons may trigger CGRP release in the VTA to explain the 130 
observations discussed above. 131 
 132 
In contrast to amylin, the acute effect of GLP-1 to reduce eating may be due to a 133 
paracrine effect on intestinal vagal afferents which transmit the signal to the nucleus 134 
of the solitary tract (NTS) which is adjacent to the AP. This finding is mainly based on 135 
the observation that the effect of intraperitoneal (but not intravenous) GLP-1 was 136 
blocked by subdiaphragmatic deafferentation, a technique which blocks all vagal 137 
afferent signaling from the abdomen to the brain23. Whether a direct action of GLP-1 138 
on the AP51 also plays a role under physiological conditions is still a matter of debate. 139 
Interestingly, amylin and GLP-1 sensitive AP neurons seem to constitute different 140 
populations of neurons because amylin receptors are found in amylin activated but 141 
not in GLP-1 activated AP cells34; hence the AP may be able to discriminate between 142 
effects of different signals even though their behavioral effect on eating is similar. 143 
 144 
 145 
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Amylin and GLP-1 receptor function 146 
The amylin receptor is composed of a heterodimer of the calcitonin receptor (CTR) 147 
core protein that combines with one or several receptor activity modifying proteins 148 
(RAMPs) to yield specific amylin receptors52-54. Receptor binding and mapping 149 
studies have shown a wide distribution of the amylin receptor components throughout 150 
the central nervous system, and a high density of both the CTR and RAMPs is found 151 
in the AP55-58. Recent experiments in our laboratory have shown that single amylin 152 
activated AP neurons contain all necessary components of the functional amylin 153 
receptor 1 or 3, i.e. CTR plus RAMP1 or CTR plus RAMP3, respectively; in fact, AP 154 
neurons may often contain both types of RAMPs within single cells59. The functional 155 
difference of amylin sensitive AP neurons containing the amylin1, the amylin 3, or the 156 
amylin 1/3 receptor is currently unknown.  157 
The presence of fully functional amylin receptors in the AP is consistent with the co-158 
expression of cyclic GMP (cGMP) which is one of the second messengers of amylin 159 
receptor activation25, 60, in CTR carrying AP neurons34. Another second messenger 160 
system activated by amylin is the ERK/MAPK system. Amylin leads to a 161 
phosphorylation of ERK, and this effect may be involved in the rapid effects of amylin 162 
on eating because at least under certain conditions, inhibition of ERK 163 
phosphorylation prevented the effect of amylin61.  164 
Part of the amylin activated AP neurons seem to express dopamine-beta-hydroxylase 165 
(DBH) which characterizes noradrenergic neurons. In fact, roughly 50% of amylin 166 
activation seems to occur in neurons expressing DBH39, 62 while the phenotype of the 167 
remainder of amylin activated neurons is unclear; at least part of them may be 168 
second order neurons which therefore do not necessarily express amylin receptors 169 
and the amylin signaling transduction machinery themselves. 170 
 171 
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Interestingly, even though circulating GLP-1 also may directly activate AP neurons51 172 
and even though the general brain activation pattern after amylin or GLP-1 injection 173 
shows many similarities and a large overlap among affected regions33, amylin 174 
sensitive AP neurons seem to form a population of neurons that is different from 175 
GLP-1 sensitive AP neurons; this is based on the presence or absence of the CTR in 176 
amylin versus GLP-1 activated AP neurons, respectively 34. Further, GLP-1’s eating 177 
inhibitory action seems to differ between fasted versus fed animals because GLP-1 178 
decreased eating when administered to rats after refeeding with a 3g meal, but not 179 
when administered in the fasted state63; amylin, in contrast, has been shown to 180 
reduce eating when administered to fasted or ad libitum fed animals (e.g., 43, 62, 64). 181 
The increased effectiveness of GLP-1 to reduce eating in refed animals may be 182 
related to an increase in the GLP-1 receptor translocation to the cellular membrane of 183 
vagal afferent neurons; the cell bodies of these neurons are located in the nodose 184 
ganglion. These neurons mediate the satiating effect of GLP-123 but the increased 185 
effectiveness of GLP-1 in refed animals (which coincides with this receptor 186 
translocation) may indicate that GLP-1 also controls postprandial satiety63. 187 
 188 
 189 
Effects of amylin and GLP-1 on energy expenditure 190 
Energy balance is determined by gross energy intake, energy expenditure and 191 
energy loss via faeces, fermentation gases or urine. Here, I briefly want to summarize 192 
effects of amylin and GLP-1 on energy expenditure, all reported results are based on 193 
the assessment of energy expenditure by indirect calorimetry. Generally, 194 
manipulations that result in changes of eating or body weight are often accompanied 195 
by alterations in energy expenditure. Usually, body weight reduction by dieting leads 196 
to an adaptive physiological response to reduce energy expenditure; this response 197 
helps the body to minimize the potential negative effects of long term energy 198 
restriction in a state of negative energy balance (“starvation response”). Interestingly, 199 
both amylin and GLP-1 may at least partly counteract this response.  200 
Some of the earlier studies showed that acute administration of the amylin receptor 201 
agonist sCT increased energy expenditure in the absence of food65, 66; further, 202 
chronic peripheral administration of amylin also increased energy expenditure in rats 203 
and this effect was paralleled by a decrease in eating and body weight gain. Further, 204 
the effect of amylin to increase energy expenditure was markedly enhanced in mice 205 
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overexpressing the amylin receptor component RAMP1 which indicates an important 206 
role of the amylin-1 receptor; this effect seemed to be paralleled by increased 207 
activation of the sympathetic outflow to enhance brown adipose tissue 208 
thermogenesis67. The latter effect is in line with experiments showing that the effect 209 
of peripheral or central amylin on energy expenditure can be blocked by co-210 
administration of a beta-adrenergic receptor antagonist68.  211 
The site of amylin action for these effects has not yet been investigated in detail but 212 
the AP may play some role; acute injections of amylin or sCT into the AP increased 213 
energy expenditure at a dose approximately 1000 times lower than peripherally 214 
effective doses. During chronic administration, amylin infused into the AP was also 215 
able to prevent the decrease in energy expenditure seen in rats whose food intake 216 
was yoked to the amylin treated rats69. The brain pathways linking the presumed 217 
primary site of action in the AP69 and enhanced sympathetic output67 are currently 218 
unknown. 219 
Similar to amylin, GLP-1 or its agonists also seem to increase energy expenditure 220 
under some but not all70 experimental conditions; the effect is dose dependent and 221 
seems to be most robust when GLP-1 is administered centrally71. Interestingly, a 222 
recent study also indicated that GLP-1 may be involved in the control of energy 223 
expenditure in humans because the inhibition of GLP1-breakdown by a dipeptidyl 224 
peptidase IV inhibitor increased energy expenditure in men72. 225 
Overall, these studies indicate that amylin and GLP-1 seem to modulate energy 226 
metabolism both via an effect on food intake and on energy expenditure, but the 227 
former effect is characterized far more extensively than the latter.  228 
 229 
Interactions of amylin with other factors involved in the control of energy 230 
metabolism 231 
Amylin and leptin 232 
Consistent with the concept that long term “adiposity signals” may modulate the 233 
effectiveness of meal associated satiation (“short term”) signals73, 74, a number of 234 
recent studies investigated the interactions between amylin and leptin. One of the 235 
first studies in respect to amylin reported that rodent models with a defective leptin 236 
signalling system have a reduced response to anorectic doses of the amylin agonist 237 
sCT75. Subsequently, we reported that acute administration of leptin to the third 238 
ventricle increased the eating-inhibitory effect of peripheral amylin 76.  239 
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Interest in this type of interaction was fueled by the finding that amylin may be able to 240 
reduce the leptin resistance that is commonly associated with obesity 77-80. Leptin 241 
resistant obese rats were “re-sensitized” to leptin by chronic amylin administration 81. 242 
In other words, amylin which itself is still effective in obese rats3, 82, 83 reduced eating 243 
and body weight significantly more when leptin was co-administered with amylin81, 84-244 
86. The effect of amylin on leptin’s action and leptin sensitivity appeared to be specific 245 
to amylin 81 because the effects were not seen to the same extent with the GLP-1 246 
analog AC3174 81, or when infusions of leptin were combined with the GLP-1 247 
receptor agonist exendin-4 87. Leptin combined with GLP-1 analogs did produce 248 
stronger effects on eating and body weight than single compounds, but the 249 
interaction seemed to be (mathematically) additive rather than synergistic 88. Further, 250 
and in contrast to the amylin-induced sensitization of animals to leptin, the effect was 251 
only present in animals that had already lost a substantial amount of weight or after 252 
animals were switched from an obesogenic high fat diet to regular rodent chow 89; 253 
hence, manipulations which themselves may affect leptin sensitivity. 254 
The amylin/leptin combination also had increased effects on energy expenditure 81. 255 
The effect of the amylin/leptin combination on energy balance appeared to be 256 
paralleled by a preferential oxidation of fat as indicated by the low respiratory quotient 257 
in both the amylin/leptin and the pair-fed groups 81, 84-86; importantly, the lower 258 
respiratory quotient was still evident in amylin/leptin co-injected animals during the 259 
weight stable phase and not only during weight loss like in the pair-fed group 81, 85, 90-260 
92.  261 
All effects combined, the amylin/leptin combination treatment prevented the 262 
suppression of energy metabolism that is typically seen in situations of negative 263 
energy balance which may e.g. be induced by simple dieting. The potential 264 
mechanisms of this interaction have been summarized recently85, 93, 94. Briefly, most 265 
data indicate that the hypothalamus, and in particular the ventromedial hypothalamus 266 
is critically involved in this interaction. Amylin strongly enhanced leptin signalling 267 
specifically in the ventromedial hypothalamus, and this was also confirmed under in 268 
vitro conditions 81, 85 95 96, 97. Amylin also increased leptin binding in the ventromedial 269 
hypothalamus and other hypothalamic sites, e.g. the dorsomedial hypothalamus 270 
(DMH) 85 while leptin receptor expression was reduced in the mediobasal 271 
hypothalamus in amylin-deficient mice 85.  272 
10 
A recent study indicated that interleukin-6 (IL-6) seems to be involved in the leptin-273 
sensitizing effect of amylin. Amylin induced the increased synthesis and release of IL-274 
6 from hypothalamic microglia which seems to act on leptin-receptor positive neurons 275 
in the ventromedial hypothalamus to improve hypothalamic leptin signaling. This was 276 
corroborated by the finding that rats treated with antibodies against IL-6 or mice 277 
deficient for IL-6 did not show the same enhancing effect of amylin on leptin signaling 278 
compared to their respective controls 98.  279 
Finally, and consistent with earlier studies that leptin-deficient ob/ob mice are less 280 
sensitive to sCT 75, we recently showed that leptin receptor deficient db/db mice or 281 
Zucker ZDF rats respond less to acute amylin injections than respective wildtype 282 
controls; further, the reduction of body weight and adiposity by leptin was lower in 283 
amylin-deficient mice than in wildtype controls 85, and amylin-deficient mice had less 284 
leptin induced pSTAT3 formation in the ventromedial hypothalamus 85. In other words, 285 
endogenous leptin action may be required for a full action of amylin and the presence 286 
of amylin signaling may mutually be necessary for the full effect of leptin. 287 
 288 
 289 
Amylin and CCK 290 
Next to the interaction between amylin and leptin, the combined effects of amylin and 291 
CCK on eating has attracted most interest. Amylin and CCK reduce eating mainly by 292 
a meal size effect and their combined administration leads to a stronger reduction in 293 
eating than single administration99, 100. The effect seems to be synergistic because 294 
ineffective doses of amylin and CCK combined to produce near maximal reductions 295 
in eating.  296 
A series of experiments indicated that CCK’s anorectic action may be partly mediated 297 
by amylin and that amylin is a necessary modulator of CCK’s effect because the 298 
eating inhibitory effect of CCK can be attenuated by amylin receptor antagonists 101, 299 
102. Further, amylin was necessary for the full eating inhibitory effect of CCK because 300 
CCK’s action was nearly abolished in amylin deficient compared to control mice; this 301 
effect could be rescued because co-administration of a subthreshold dose of amylin 302 
with CCK restored normal CCK responsiveness103. 303 
 304 
 305 
 306 
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 309 
Amylin and estradiol 310 
Food intake in mammals is sexually differentiated and estradiol plays the major role in 311 
gender specific effects in females. One important effect of estradiol is to increase the 312 
effectiveness of satiating hormones like CCK; this effect, e.g., contributes to the cyclic 313 
decrease in eating in female rats on their day of estrus104-106.  314 
Trevaskis and colleagues 107 were the first to test the effect of amylin in female rats 315 
specifically in the presence or absence of estradiol. Surprisingly, eating and body 316 
weight in ovariectomized rats was reduced more by chronic amylin than in intact 317 
control rats or in ovariectomized rats receiving physiological estradiol replacement. 318 
Body adiposity also tended to be reduced by amylin in the ovariectomized compared 319 
to sham operated or estradiol replaced rats 107. The mechanisms underlying the 320 
effect of estradiol remained unclear but it was shown that ovariectomized rats had 321 
reduced neurogenesis in particular in the AP and that chronic amylin restored this 322 
effect. Theoretically, increased neurogenesis may lead to an increase in the number 323 
of amylin receptors or amylin responsive cells in the AP, but this remains to be 324 
studied.  325 
More recent data from our own lab indicate that the interaction between amylin and 326 
estradiol seems more complex. Under conditions of acute amylin administration, 327 
single amylin injections reduced eating more effectively in estradiol replaced rats than 328 
in ovariectomized rats without physiological estradiol replacement108, 109. Hence, 329 
future experiments need to clarify whether the role of estradiol in modulating amylin 330 
action depends on the experimental conditions or whether a common mechanism 331 
under acute or chronic conditions can be identified. 332 
 333 
GLP-1 and estradiol 334 
Similar to CCK and amylin, the eating inhibitory effect of GLP-1 also seems to be 335 
enhanced by estradiol because physiological estradiol replacement in ovariectomized 336 
rats enhanced GLP-1’s action74. Further, a recent study showed that non-337 
physiological replacement of estrogen in the form of a GLP-1/estrogen conjugate 338 
lead to a stronger decrease in eating and body weight than GLP-1 alone 110. The 339 
mechanisms underlying these effects have not been studied yet. 340 
12 
 341 
Amylin as a potential treatment strategy against obesity 342 
Basic research findings on the interaction between amylin and leptin have been 343 
described above. Because obese animals and humans are often leptin resistant and 344 
hence unresponsive to exogenous leptin, the finding that amylin increases leptin 345 
sensitivity and that amylin may therefore be able to overcome leptin resistance in 346 
obese individuals is of high clinical relevance. Clinical trials tested the combined use 347 
of the amylin analogue pramlintide as adjunct therapy with insulin for the treatment of 348 
type 1 and type 2 diabetes; these trials showed that treatment of diabetic persons 349 
with insulin plus pramlintide improved glycemic control and also lead to a significant 350 
body weight loss compared to insulin monotherapy 111. Pramlintide was subsequently 351 
shown to reduce energy intake in type 2 diabetics and obese non-diabetics112-115.  352 
Similar to experiments in rodents, the combination of the amylin and leptin analogues 353 
pramlintide and metreleptin, respectively, was effective in lowering body weight and 354 
adiposity in humans 81, 116. The clinical data were encouraging and future work will 355 
have to test the effects of prolonged treatment, potential side effects, and the 356 
consequences of cessation of treatment. Similar to treatment of diabetics with insulin, 357 
the maintenance of body weight loss may require continuous therapy because the 358 
weight lowering effect seems to fade on discontinuation of treatment (see also 92, 93, 359 
117). 360 
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Pramlintide releasing fat sensors 362 
Recently, an interesting experimental approach to reduce eating and body weight has 363 
been reported118. The authors of this study produced a self-controlled release device 364 
for the amylin analogue pramlintide. Cells were manipulated in a way that they 365 
contained a closed-loop genetic circuit which constantly monitored blood fatty acid 366 
levels and which was coupled to the coordinated and reversible expression and 367 
release of pramlintide. The fatty acid sensor was based on the peroxisome 368 
proliferator-activated receptor-α. This sensor which was sensitive to a broad 369 
spectrum of fatty acids, was subsequently shown to be activated in a reversible 370 
manner in vitro and also in vivo, e.g. when manipulated cells were administered to 371 
mice as intraperitoneal implants. Most importantly, increasing amounts of dietary fat 372 
led to an enhanced release of pramlintide which resulted in reduced eating and body 373 
weight in mice on a high fat but not on a low fat diet118. Whether this strategy can be 374 
employed clinically needs to be studied in coming years. 375 
 376 
 377 
Summary 378 
This review briefly summarizes some recent findings in respect to the control of 379 
eating and body weight by amylin and GLP-1. Both hormones or their respective 380 
analogues also seem to be active in humans. While the use of amylin analogues, in 381 
particular in combination with leptin, is still at the experimental phase, the GLP-1 382 
analogue liraglutide has recently been approved for anti-obesity treatment in the USA. 383 
 384 
385 
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